Semax
A synthetic ACTH(4-10)-derived heptapeptide studied in neurotrophic, cognitive and neuroprotection research
- Fulfillment Origin
- us
Semax is a synthetic linear heptapeptide derived from the ACTH(4-10) sequence. Research has examined its effects on neurotrophic signaling, monoamine regulation, memory-related processes, ischemic models and stress-responsive gene expression. This dossier summarizes compound-level research and is intended only for laboratory reference.
Synthetic linear heptapeptide · ACTH(4-10) analog
- Formula
- C37H51N9O10S
- Molecular weight
- 813.93 g/mol
- Form
- Lyophilized powder
- CAS / ID
- 80714-61-0
Independently tested. Verifiably pure.
Every batch of Semax is reviewed against its independent laboratory documentation before fulfillment.
- HPLC Purity AnalysisReported purity: Lot-specific purity — see COA
- Mass SpectrometryMass-spectrometric identity — see lot COA
- Heavy Metals ScreeningLot-specific result — see COA
- Endotoxins (LPS)Lot-specific result — see COA
- Sterility TestingLot-specific result — see COA
- Net Peptide ContentLot-specific result — see COA
- HPLC Purity
- Lot-specific purity — see COA
- Identity
- Mass-spectrometric identity — see lot COA
- Endotoxin (LAL)
- Lot-specific result — see COA
- Lab
- Independent third-party laboratory
Not for human or veterinary use. For in-vitro laboratory research only. This product is not intended to diagnose, treat, cure, or prevent any disease.
A seven-residue peptide built from the ACTH(4-10) sequence.
Semax is composed of seven amino-acid residues arranged as Met-Glu-His-Phe-Pro-Gly-Pro. The peptide preserves the core ACTH(4-10) sequence while remaining structurally distinct from the full adrenocorticotropic hormone.
Linear heptapeptide
A seven-residue synthetic peptide with a defined primary sequence.
Met-Glu-His-Phe-Pro-Gly-Pro
Often abbreviated MEHFPGP.
Neurotrophic and cognitive signaling
Published work has focused on BDNF-linked pathways, monoamine systems and neuronal stress responses.
The Semax molecule visualized.
The animated structure illustrates the compound's linear seven-residue peptide framework and elemental composition.
Published research areas associated with Semax.
The summaries below reflect preclinical and clinical literature themes and are not instructions for administration or use.
Brain-derived neurotrophic factor
Research has reported changes in BDNF expression in selected brain regions and experimental models.
Serotonin and dopamine modulation
Preclinical studies have examined serotonergic, dopaminergic and noradrenergic signaling.
Neuroprotection research
Semax has been evaluated in cerebral ischemia and oxidative-stress models.
Semax signaling pathways visualized.
The pathway animation separates neurotrophic, monoaminergic and cellular-stress research themes.
Neurotrophic signaling
Semax research has examined changes in BDNF expression and related receptor signaling.
Monoamine modulation
Experimental work has reported effects on serotonin, dopamine and norepinephrine-associated systems.
Neuroprotection pathways
Studies have investigated oxidative stress, inflammatory gene expression and neuronal survival in ischemic models.
How Semax differs from conventional stimulant research compounds.
Semax is a peptide studied through neurotrophic and regulatory pathways rather than as a classical small-molecule stimulant.
Peptide
Semax is a defined seven-residue peptide.
Neurotrophic regulation
BDNF and gene-expression pathways are prominent in the literature.
Multi-system modulation
Research spans monoamine signaling, neuroplasticity and cellular stress responses.
| Material class | Primary research pathway | Molecular type | Typical research context |
|---|---|---|---|
| Semax | Neurotrophic and monoamine signaling | Linear heptapeptide | Cognition, ischemia models and stress-response research |
| Classical stimulant compounds | Direct neurotransmitter transport or release | Small molecule | Acute arousal and behavioral activation research |
Research emphasis visualized.
These bars summarize literature emphasis and are not receptor-binding affinity values.
Semax exposure is formulation- and route-dependent.
Research findings should be interpreted in the context of the specific formulation, species, route and study design. A universal half-life should not be assigned to lyophilized research material.
Enzymatic degradation matters
Linear peptides may be sensitive to proteolytic degradation depending on the biological matrix.
Do not generalize across formulations
Published exposure data may not transfer between experimental preparations.
Use analytical documentation
Identity and peptide content should be verified using the actual batch COA.
Full specification.
The fields below describe the compound identity. Final analytical values must match the actual Aurelia lot documentation.
Semax
Synthetic ACTH(4-10)-derived heptapeptide.
Met-Glu-His-Phe-Pro-Gly-Pro
Seven amino-acid residues.
C37H51N9O10S
Elemental composition of Semax.
813.93 g/mol
Calculated molecular mass.
80714-61-0
Commonly referenced Semax identifier.
See lot COA
Confirm identity, purity, net peptide content and applicable contaminant testing.
From peptide exposure to downstream signaling.
This is an illustrative research sequence, not a dosing or treatment timeline.
Peptide interaction
Semax enters the experimental system as a defined seven-residue peptide.
Neurotrophic gene response
BDNF and related signaling pathways may change in selected models.
Monoamine-system modulation
Serotonergic, dopaminergic and noradrenergic pathways are evaluated.
Functional endpoints
Researchers assess memory, neuronal survival, gene expression and stress-response outcomes.
Handle as a sensitive linear peptide.
Follow supplier-validated storage documentation for the supplied lot and record all preparation conditions.
Cold, dry and protected
Minimize moisture, heat, direct light and repeated temperature cycling.
Matrix and time matter
Working stability depends on solvent, concentration, pH, container and temperature.
Track lot and hold time
Document preparation time, storage temperature and elapsed time before analysis.
- Record the batchLink each experiment to the vial lot and its corresponding COA.
- Minimize cyclingAvoid unnecessary freeze-thaw or warming cycles.
- Use validated containersSelect materials appropriate for low-concentration peptide solutions.
- Document preparationRecord solvent, concentration, pH, temperature and hold time.
For in-vitro laboratory research only. Not for human or veterinary use.
Semax literature library.
The publications below provide context for Semax neurotrophic, cognitive and neuroprotection research.
A review of the compound's development and cognitive research profile.
View primary source →Research examining neuronal protection and functional outcomes in ischemic conditions.
View primary source →Experimental work evaluating neurotrophin-related gene-expression changes.
View primary source →A study of transcriptional responses associated with Semax exposure.
View primary source →References.
Independent literature supporting the molecular and mechanistic context used in this dossier.
- Ashmarin IP et al. Semax, an ACTH(4-10) analogue with cognitive-enhancing properties. Neurosci Behav Physiol. 2006.Open source ↗
- Gusev EI et al. Neuroprotective effects of Semax in conditions of cerebral ischemia. Neurosci Behav Physiol. 2010.Open source ↗
- Agapova TYu et al. Semax modulates the expression of neurotrophins and their receptors. Bull Exp Biol Med. 2010.Open source ↗
- Agapova TYu et al. Molecular mechanisms underlying the effects of Semax on hippocampal gene expression. Bull Exp Biol Med. 2011.Open source ↗
Related products
L-Glutathione
MOTS-c
NAD+
Pinealon
Selank
